Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Appili Therapeutics Inc. (T:APLI)

Business Focus: Bio Therapeutic Drugs

Feb 13, 2024 05:49 pm ET
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the...
Dec 15, 2023 07:27 am ET
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the United States Patent and Trademark Office (“USPTO”) has published patent claims for ATI-1701 under the U.S. Application No. 16/982,322
Nov 13, 2023 04:24 pm ET
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the second quarter of its fiscal year 2024, which ended on September 30, 2023. All figures are stated in Canadian dollars unless otherwise stated.
Oct 25, 2023 07:49 am ET
Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the company secured a commitment for the second stage of funding for ATI-1701 from the U.S. Air Force Academy (“USAFA”), who is working in partnership with the Defense Threat Reduction Agency (“DTRA”), the funding agency.
Sep 27, 2023 07:21 pm ET
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual meeting of shareholders held earlier today.
Sep 27, 2023 07:27 am ET
Appili Therapeutics Presents at the 10th International Tularemia Conference
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, and key members of Appili’s scientific team, will participate at the 10th International Tularemia Conference, from September 24 to 26, 2023. Dr. Gelhaus will present an update on Appili’s biodefense vaccine program
Sep 25, 2023 07:54 am ET
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC (“Saptalis”) received approval from the U.S. Food and Drug Administration ("FDA”) for Metronidazole Oral Suspension 500mg/5mL (
Aug 11, 2023 04:50 pm ET
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the first quarter of its fiscal year 2024, which ended on June 30, 2023. All figures are stated in Canadian dollars unless otherwise stated.
Jun 29, 2023 07:26 am ET
Appili Therapeutics Announces Bridge Loan from Bloom Burton & Co.
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that it has entered into a definitive agreement with respect to an unsecured C$300,000 bridge loan (the “Bridge Loan”) from Bloom Burton & Co. Inc. (the “Lender”).
Jun 23, 2023 05:07 pm ET
Appili Therapeutics – Press Release Correction
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), announced today a correction to its press release entitled “Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results” which was issued on June 23, 2023 (the “Initial Press Release”).
Jun 23, 2023 07:21 am ET
Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the fiscal year ended March 31, 2023, and provided an update on the Company’s strategy for fiscal 2024. All figures are stated in Canadian dollars unless otherwise stated.
May 24, 2023 07:19 am ET
Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the United States Patent and Trademark Office (“USPTO”) has published patent claims for ATI-1501 under the U.S. Application No. 18/072,154 filed on November 30, 2022 and titled “Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same”. The patent covers the composition and preparation methods for the drug through 2039.
May 08, 2023 07:38 am ET
Appili Therapeutics Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the Company has executed the initial contract with the U.S. Air Force Academy (USAFA) for the previously announced funding of the ATI-1701 program. This contract represents the first stage of funding from the previously announced award from the U.S. Department of Defense (“DOD”). This initial funding, in the amount of US$7.3 million, will be used to kick-off ATI-1701 early-stage development and regul
Apr 18, 2023 07:17 am ET
Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Dr. Don Cilla, Appili President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference taking place on April 25 and 26, 2023.
Apr 03, 2023 07:22 am ET
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that it has appointed biopharmaceutical industry veteran Gary Nabors, Ph.D., to serve as Appili’s Chief Development Officer. Dr. Nabors joins Appili effective April 3, 2023, and will lead the advancement of programs through development, regulatory submission and key commercialization milestones.
Mar 20, 2023 07:18 am ET
Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that it has entered into an amended and restated secured loan agreement (the “Amended Loan Agreement”) with Long Zone Holdings Inc. (“LZH”), amending and restating the original secured loan agreement by and between Appili and LZH dated March 25, 2022 (the “Original Loan Agreement”).
Feb 14, 2023 07:18 am ET
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal year 2023, which ended on December 31, 2022.
Feb 08, 2023 07:18 am ET
Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA
Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today, with its partner Saptalis Pharmaceuticals LLC (“Saptalis”), announced that the Food and Drug Administration (“FDA”) accepted the ATI-1501 New Drug Application (“NDA”). ATI-
Jan 17, 2023 07:12 am ET
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus, Ph.D., as Director of Non-Clinical Research, and Arthur Baran, B.Sc., MBA, PMP, as Director of New Product Development including ATI-1701, a
Jan 13, 2023 07:19 am ET
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance of new patent claims for ATI-1501, Appili’s liq
Nov 14, 2022 07:45 am ET
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that the U.S. Department of Defense (“DOD”), via the Joint Science and Technology Office of the Defense Threat Reduction Agency (“DTRA”) in partnership with the U.S. Air Force Academy (“USAFA”), will provide at least US$14 million in funding over two years to fund the development of ATI-1701. ATI-1701 is a potential first-in-class vaccine candidate for the prevention of infection with aerosolized Franc
Nov 10, 2022 07:38 am ET
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the second quarter of its fiscal year 2023, which ended on September 30, 2022.
Sep 22, 2022 06:43 pm ET
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today.
Aug 12, 2022 04:54 pm ET
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its fiscal year 2023, which ended on June 30, 2022.
Aug 02, 2022 07:38 am ET
Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that Armand Balboni, M.D, Ph.D, Chief Executive Officer, and Yoav Golan, M.D, Chief Medical Officer of Appili, will participate at the seventh iteration of WorldLeish
Jun 29, 2022 07:49 am ET
Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the fiscal year ended March 31, 2022, and provided an update on the Company’s strategy for fiscal 2023. All figures are stated in Canadian dollars unless otherwise stated.
May 26, 2022 09:11 am ET
Appili Therapeutics Announces Closing of Public Offering of $4,500,000
Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”) announced the closing of its previously announced public offering (the “Offering”) of units (the “Units”). The Offering was made pursuant to an agency agreement, as amended, entered into between the Company, Bloom Burton Securities Inc. (the “Lead Agent”) and Leede Jones Gable Inc. (collectively with the Lead Agent, the “Agents”).
May 18, 2022 09:07 am ET
IIROC Trade Resumption - APLI
TORONTO, May 18, 2022 /CNW/ - Trading resumes in:
May 18, 2022 08:55 am ET
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering
Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”) is pleased to announce today that it has priced its previously announced overnight marketed offering of equity securities (the "Offering"). Pursuant to the Offering, Appili will issue 50,000,000 units of the Company ("Units") at a price of C$0.09 per Unit (the “Offering Price”) for gross proceeds of C$4,500,000. Each Unit is comprised of one Class A common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant is exercisable at a price of C$0.15 an
May 17, 2022 04:16 pm ET
IIROC Trading Halt - APLI
TORONTO, May 17, 2022 /CNW/ - The following issues have been halted by IIROC:
May 17, 2022 04:05 pm ET
Appili Therapeutics Announces Overnight Marketed Equity Offering
Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that it will undertake an overnight marketed public offering (the "Offering") of units (the "Units"), comprised of Class A common shares and Class A common share purchase warrants ("Warrants"). The Offering is to be effected on a best efforts agency basis in each Province of Canada (other than Quebec) by way of a prospectus supplement (the "Prospectus Supplement") to the Company's base shelf prospectus dated May 16, 2022 (the “Base S
Apr 27, 2022 07:37 am ET
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that Stéphane Paquette, Vice President, Corporate Development, will present at the Bloom Burton & Co. Healthcare Investor
Apr 13, 2022 07:42 am ET
Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced the addition of ATI-1801, a clinical stage topical paromomycin product to treat cutaneous leishmaniasis, to its development pipeline. Licensed from the US Department of Defense (“DOD”) via the US Army Medical Materiel Development Activity (“USAMMDA”), ATI-1801 is a novel topical product with demonstrated safety and efficacy in a Phase 3 study. Appili will be working with international partners to complete the remaining
Mar 29, 2022 07:36 am ET
Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and License and Distribution Agreement with Long Zone Holdings
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that it has entered into a senior secured loan and exclusive license and distribution agreement (the “Agreement”) with Long Zone Holdings Inc. (“LZH”), led by Jonathan Ross Goodman, founder of both Paladin Labs Inc. and Knight Therapeutics Inc. (TSE: GUD). The US$3.6 million senior secured loan will be used by Appili to retire the previously announced senior convertible funding agreement with The Lind Partners and for w
Mar 09, 2022 08:19 am ET
Appili Therapeutics to Present Live via Webcast at OTC Markets Virtual Life Sciences Investor Forum
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that Stéphane Paquette, Vice President, Corporate Development, will...
Feb 28, 2022 07:40 am ET
Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that the U.S. Department of Defense (“DOD”), via the Joint Science and Technology Office of the Defense Threat Reduction Agency (“DTRA”), has selected for funding an Appili proposal that would provide over US$10 million to advance the Company’s biodefense vaccine candidate
Feb 14, 2022 05:10 pm ET
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced its financial and operational results for the third quarter of its fiscal year 2022, which ended on December 31, 2021.
Feb 08, 2022 07:17 am ET
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, announced today it has amended its agreement with Saptalis Pharmaceuticals LLC (“Saptalis”), a New York-based specialty pharmaceuticals company, to expand the territories in which Saptalis will commercialize
Dec 23, 2021 07:17 am ET
Appili Therapeutics – Press Release Correction
Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”) announced today a correction to its press release entitled “Appili Therapeutics Announces Update to Funding Agreement with The Lind Partners” which was issued on December 22, 2021 (the “Initial Press Release”).
Dec 22, 2021 07:41 am ET
Appili Therapeutics Announces Update to Funding Agreement With The Lind Partners
Appili Therapeutics Inc. (TSX:APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, announced today that the Company and Lind Global Fund II, LP, an investment entity managed by The Lind Partners, a New York based institutional fund manager (together "Lind"), have agreed to amend certain terms of the
Nov 19, 2021 07:42 am ET
Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors
The results reported today are from the final challenge timepoint in a preclinical study evaluating the efficacy of ATI-1701 28 days, 90 days, and one year after vaccination. At each challenge timepoint, cohorts of vaccinated and unvaccinated animals received a lethal exposure of aerosolized Francisella tularensis, the causative agent of tularemia.
Nov 12, 2021 05:41 pm ET
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2022, which ended on September 30, 2021.
Nov 12, 2021 07:19 am ET
Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that the Phase 3 PRESECO (PREventing SEvere COVID-19) clinical trial evaluating oral antiviral Avigan®/Reeqonus™(f
Nov 12, 2021 07:01 am ET
IIROC Trade Resumption - APLI
TORONTO, Nov. 12, 2021 /CNW/ - Trading resumes in:
Nov 11, 2021 11:16 am ET
IIROC Trading Halt - APLI
TORONTO, Nov. 11, 2021 /CNW/ - The following issues have been halted by IIROC:
Oct 14, 2021 09:35 am ET
Appili Therapeutics Announces Closing of Public Offering of $7,000,220
Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”) announced the closing of its previously announced public offering (the “Offering”) of units (the “Units”). The Offering was made pursuant to an agency agreement entered into with a syndicate of agents led by Bloom Burton Securities Inc. (the “Lead Agent”) and including iA Private Wealth Inc., Leede Jones Gable Inc., Research Capital Corporation, and Richardson Wealth Limited (collectively with the Lead Agent, the “Agents”) and the Company.
Oct 07, 2021 09:57 am ET
IIROC Trade Resumption - APLI
TORONTO, Oct. 7, 2021 /CNW/ - Trading resumes in:
Oct 07, 2021 09:07 am ET
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering
Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”) is pleased to announce today that it has priced its previously announced overnight marketed offering of equity securities (the "Offering"). Pursuant to the Offering, Appili will issue 8,434,000 units of the Company ("Units") at a price of C$0.83 per Unit (the “Offering Price”) for gross proceeds of C$7,000,220. Each Unit is comprised of one Class A common share of the Company (a "Common Share") and one-half of one Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant is exercisable at a price of C$1.10 and
Oct 07, 2021 08:11 am ET
IIROC Trading Halt - APLI
TORONTO, Oct. 7, 2021 /CNW/ - The following issues have been halted by IIROC:
Oct 06, 2021 04:01 pm ET
Appili Therapeutics Announces Overnight Marketed Equity Offering
The Offering is subject to a number of conditions, including, without limitation, receipt of all regulatory approvals. The net proceeds of the Offering will be used primarily towards funding research and development activities for oral COVID-19 antiviral candidate Avigan®/Reeqonus™ (favipiravir), including costs associated Appili’s global Phase 3 trial evaluating Avigan/Reeqonus for the treatment of mild-to-moderate COVID-19 (PREventing SEvere COVID-19; PRESECO). Net proceeds of the Offering will also be used to support business development initiatives to expand the Company’s portfolio of prog
Sep 29, 2021 09:56 am ET
AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili Therapeutics
DUBLIN, Sept. 29, 2021 /PRNewswire/ -- AiPharma Global Holdings LLC ("AiPharma"), a private biopharmaceutical research, development, and commercialization company, and Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) ("Appili"), a biopharmaceutical company focused on drug development for infectious diseases, announced today a strategic alliance to advance the global development of Avigan®/Reeqonus™ (favipiravir), a broad-spectrum oral antiviral currently being evaluated by Appili for the potential treatment and prevention of COVID-19. AiPharma and Appili entered into a strategic alliance a
Sep 29, 2021 07:39 am ET
Appili Therapeutics and AiPharma Announce Strategic Alliance and Equity Transaction
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, and AiPharma Global Holdings LLC (“AiPharma”), a private pharmaceutical research, development and commercialization company, today announced a strategic alliance to advance the global development of Avigan®/Reeqonus™ (favipiravir), a broad-spectrum oral antiviral currently being evaluated by Appili and its
Sep 23, 2021 07:48 am ET
Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus™ for the Treatment of Mild-to-Moderate COVID-19
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced it has completed enrollment in its global Phase 3 PRESECO (PREventing SEvere COVID-19) trial evaluating oral
Sep 20, 2021 07:44 am ET
Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus™ for COVID-19 Patients
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced it entered into an agreement with FUJIFILM Toyama Chemical Co., Ltd. (“FFTC”), that will provide funding support for its Phase 3 PRESECO (PREventing SEvere COVID-19) clinical trial. The new funding of $1,000,000 USD was secured from FFTC, one of the Company’s partners in a
Sep 17, 2021 07:17 am ET
Appili Therapeutics Announces Completion of Patient Enrollment for Avigan®/Reeqonus™ Viral Shedding Sub- Study for Mild-to-Moderate COVID-19 Patients
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced it has completed patient enrollment in the viral shedding sub-study portion of its Phase 3 PRESECO (PREventing SEvere COVID-19) trial evaluating
Sep 08, 2021 07:17 am ET
Appili Therapeutics Announces Results for Resolutions at Annual General Meeting of Shareholders
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced the results from its annual general meeting of shareholders held on Tuesday, September 7, 2021. The Company also announced the addition of Josef Vejvoda to its Board of Directors (the “Board”).
Aug 18, 2021 08:24 am ET
Appili Therapeutics Announces Closing of $3.5 Million Funding Agreement
Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that it has closed its $3.5 million convertible security funding agreement (the “Agreement”) with Lind Global Fund II, LP, an investment entity managed by The Lind Partners, a New York based institutional fund manager. Details of the Agreement were previously disclosed in the Company’s
Aug 13, 2021 07:17 am ET
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2022
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the first quarter of its fiscal year 2022, which ended on June 30, 2021.
Aug 09, 2021 07:15 am ET
Appili Therapeutics Secures $3.5 Million in Funding
Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that it has entered into a $3.5 million convertible security funding agreement (the “Agreement”) with Lind Global Fund II, LP, an investment entity managed by The Lind Partners, a New York based institutional fund manager (together "Lind").
Jun 24, 2021 07:17 am ET
Appili Therapeutics Reports Fiscal Year 2021 Financial and Operational Results and Provides Update on Strategy for Fiscal 2022
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the fiscal year ended March 31, 2021, and provided an update on the Company’s strategy for fiscal 2022. All figures are stated in Canadian dollars unless otherwise stated.
Jun 17, 2021 07:17 am ET
Appili Therapeutics Inc. Expands PRESECO Clinical Trial of Avigan®/Reeqonus™ for Mild-to-Moderate COVID-19 Patients into Mexico and Brazil
Appili Therapeutics Inc. (TSX: APLI) (OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, has added several clinical research sites in Mexico and Brazil to its Phase 3 clinical trial evaluating Avigan®/Reeqonus™ (favipiravir) as a potential oral therapy for patients with mild-to-moderate COVID-19. The expansion into Mexico and Brazil will ensure a timely completion of this pivotal trial and reaffirm favipiravir as one of the most advanced oral COVID-19 antiviral candidates in development with top-line data expected in Q3 2
Apr 19, 2021 07:17 am ET
Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021
Appili Therapeutics Inc. (TSX:APLI; OTCQX:APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that the Company’s Chief Executive Officer, Dr. Armand Balboni will present at the fully virtual Bloom Burton & Co. Healthcare Investor C
Mar 17, 2021 07:17 am ET
Appili Therapeutics to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference on Friday, March 19th
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it will present at the fully virtual Inaugural Emerging Growth Virtual Conference, presented by M Vest
Mar 02, 2021 06:01 am ET
Appili Therapeutics to Host Drs. Scott Gottlieb and Syra Madad in Virtual Fireside Chat Discussing COVID-19: What We’ve Learned About Pandemic Responses, and Where We Go From Here
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced additional details on its webinar series examining major trends in the global infectious disease landscape. The first event, scheduled for March 3 at 1:00 p.m. ET, will feature Dr. Scott Gottlieb, Dr. Syra Madad, and Dr. Josh Schimmer. The panel will discuss the need for investing in an arsenal of treatments, preventatives, and public health policies as part of pandemic response planning.
Feb 25, 2021 08:00 am ET
Appili Therapeutics to Host Drs. Scott Gottlieb and Syra Madad in Virtual Fireside Chat Discussing COVID-19: What We’ve Learned About Pandemic Responses, and Where We Go From Here
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced additional details on its webinar series examining major trends in the global infectious disease landscape. The first event, scheduled for March 3 at 1:00 p.m. ET, will feature Dr. Scott Gottlieb, Dr. Syra Madad, and Dr. Josh Schimmer. The panel will discuss the need for investing in an arsenal of treatments, preventatives, and public health policies as part of pandemic response planning.
Feb 24, 2021 07:17 am ET
Appili Therapeutics to Present as Part of Canada’s Top Three Pitches at Biocom’s Global Life Science Partnering Conference Today
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it will present at the fully virtual Biocom Global conference.
Feb 18, 2021 01:59 pm ET
Appili Therapeutics to Host Series of Virtual Fireside Chats; First Event to Feature Dr. Scott Gottlieb to Discuss Critical Need for More Options to Combat COVID-19
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its first webinar series examining major trends in the global infectious disease landscape. The first event, scheduled for March 3 at 12:00 p.m. ET, will be an engaging discussion featuring Dr. Scott Gottlieb and other speakers to address the ongoing challenges in preventing and treating the SarsCov2 virus.
Feb 12, 2021 05:05 pm ET
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the third quarter of its fiscal year 2021, which ended December 31, 2020.
Feb 02, 2021 07:17 am ET
Appili Therapeutics Appoints Veteran Healthcare Executive Rochelle Stenzler to its Board of Directors
Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced the appointment of Rochelle Stenzler to serve on its Board of Directors. A pharmacist by training, Ms. Stenzler brings to Appili’s Board extensive experience as a senior operating executive in healthcare and other industries. In addition to her role as Board Chair with Spartan Bioscience, she has previously served as President & CEO of TouchLogic Corporation; President, International Operations of TLC Laser Eye Centers
Jan 28, 2021 06:17 am ET
Appili Therapeutics Provides Enrollment Update for Its Phase 3 PRESECO Trial Evaluating the Oral Antiviral Favipiravir as an Early Treatment in COVID-19
Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, today announced that its Phase 3 PRESECO (PREventing SEvere COvid-19) clinical trial is actively recruiting participants in 12 out of 20 planned sites in the United States. Based on current forecasts, Appili believes that it will reach the enrollment threshold required to provide an interim data readout by late March 2021. PRESECO is evaluating favip
Jan 06, 2021 07:17 am ET
Appili Therapeutics to Present at the 2021 VIRTUAL H.C. Wainwright BioConnect Conference
Appili Therapeutics Inc. (TSX: APLI, OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that Appili’s CEO Dr. Armand Balboni will participate in HC Wainwright’s Bioconnect 2021 investor event. The virtual conference takes pl
Dec 22, 2020 01:11 am ET
Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS™ (favipiravir) Tablets for the Treatment of COVID-19 under Health Canada’s Int
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), Appili Therapeutics (TSX: APLI, OTCQX: APLIF) and
Dec 02, 2020 07:17 am ET
First Patient Dosed in Appili Therapeutics’ Phase 3 Clinical Trial of Avigan® Tablets (Favipiravir) for the Treatment of COVID-19 in the United States
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that investigators have dosed the first participant in its Phase 3 trial (referred to as the “PRESECO” clinical trial) evaluating oral Avigan® tablets (favipiravir) for the treatment of COVID-19. Appili has engaged
Nov 24, 2020 07:17 am ET
Health Canada Clears Appili Therapeutics for New Phase 3 Clinical Trial to Evaluate Avigan Tablets (Favipiravir) in the Prevention of COVID-19 in Exposed Individuals in the Community
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced initiation of its Phase 3 Post Exposure Prophylaxis for COVID-19 (PEPCO) study to evaluate Avigan® tablets (favipiravir) in the prevention of COVID-19. Health Canada has provided a ‘No Objection Letter (NOL)’ for Appili’s proposed study; the U.S. FDA accepted a submission of a protocol amendment to conduct the tria
Nov 13, 2020 07:17 am ET
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2021
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2021, which ended September 30, 2020.
Oct 30, 2020 09:48 am ET
IIROC Trade Resumption - APLI
TORONTO, Oct. 30, 2020 /CNW/ - Trading resumes in:
Oct 30, 2020 09:38 am ET
Appili Therapeutics Joins Dr. Reddy’s, Global Response Aid, and FUJIFILM in Advancing Avigan® Tablets for the Potential Treatment of COVID-19
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has signed a collaboration, development and supply agreement with Dr. Reddy’s Laboratories Ltd. (BSE:500124, NSE:DRREDDY, NYSE:RDY, “Dr. Reddy’s”) and Global Response Aid (“GRA”). This agreement follows on and is harmonized with the previously announced global licensing transaction (excluding Japan, Russia, and China) between DRL, GRA and FUJIFILM Toyama Chemical Co., Ltd. (“FFTC”), the originator of Avigan® tablets. The
Oct 30, 2020 09:37 am ET
IIROC Trading Halt - APLI
TORONTO, Oct. 30, 2020 /CNW/ - The following issues have been halted by IIROC:
Oct 29, 2020 07:17 am ET
Appili Therapeutics Appoints Drug Development Executive Don Cilla to the Newly Created Position of Chief Development Officer
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced that it has recruited Don Cilla, PharmD, MBA, to serve as the Company’s new Chief Development Officer (CDO), effective November 1, 2020. In this role, Dr. Cilla will oversee the strategy and execution of the preclinical and clinical programs for Appili’s anti-infective pipeline. He will be responsible for advancing programs through clinical development, regulatory submission, and commercialization milestones. He brings to this ro
Oct 27, 2020 12:30 pm ET
Appili Therapeutics to Present at TSX Life Sciences Investor Day
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that Appili’s CEO Dr. Armand Balboni will be presenting at the first-ever Life Science Investor Day Virtual Conference hosted by TSX. The
Oct 27, 2020 08:30 am ET
Appili Therapeutics Announces Additional Funding for Its ATI-1701 Biodefense Program
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced updates for the continued development of its ATI-1701 biodefense vaccine program. Appili has entered into an agreement with Ology Biosciences, a biologics contract development and manufacturing organization (CDMO), under which Ology will manufacture ATI-1701, a novel live attenuated tularemia vaccine candidate. The U.S. Department of Defense (DOD), through the Joint Science and Technology Office of the Defense Threat Reduction Agency
Oct 20, 2020 07:17 am ET
First Participants Dosed in Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir for COVID-19 Outbreak Control in Canadian Long-Term Care Homes
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that investigators enrolled and dosed the first cluster of participants in Appili’s CONTROL COVID-19 clinical trial. Appili is sponsoring the Phase 2 cluster-randomized placebo-controlled trial (cluster-RCT) evaluating the effectiveness of favipiravir as a preventative measure against COVID-19 outbreaks in long-term care (LTC) facilities. This Phase 2 trial is an integral part of Appili’s broader clinical program aimed at evalua
Sep 18, 2020 11:49 am ET
Appili Therapeutics Virtually Opens The Market
TORONTO, Sept. 18, 2020 /CNW/ - Dr. Armand Balboni, CEO, Appili Therapeutics Inc. (TSX: APLI), joined his team and Sophie Van Houtte, Head, Company Services, TMX Group, to celebrate the company's graduation from TSX Venture Exchange to Toronto Stock Exchange and open the market. 
Sep 14, 2020 07:17 am ET
Appili Therapeutics to Commence Trading on Main Board of the TSX Exchange
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Wednesday, September 16, 2020 under the Company's current trading symbol, "APLI."
Sep 11, 2020 07:17 am ET
Appili Submits Protocol for a Phase 3 Study Evaluating Favipiravir for the Treatment of Patients with COVID-19 Infections to the US FDA
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has submitted a new protocol to its open investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) to conduct a Phase 3 clinical study evaluating favipiravir in the early treatment outpatient setting for adult COVID-19 infections. Favipiravir is a broad-spectrum antiviral administered in oral tablet form. Investigators will seek to determine if favipiravir is a safe and effective treatm
Sep 10, 2020 05:05 pm ET
Appili Therapeutics to Participate in Upcoming Investor Conferences for H.C. Wainwright & Co. and Maxim Group LLC
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its leadership team will be presenting an update on Appili’s programs at two upcoming investor conferences. A copy of Appili’s investor presentation will be available on the Company’s website under the ‘Investor Overview’ page.
Aug 14, 2020 07:17 am ET
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2021
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the first quarter of its fiscal year 2021, which ended June 30, 2020.
Aug 13, 2020 07:17 am ET
Appili Therapeutics Announces Voting Results of Annual and Special Meeting of Shareholders
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced the voting results from its annual and special meeting of shareholders held on Thursday, August 12, 2020.
Aug 11, 2020 08:57 am ET
Appili Therapeutics Receives Eligibility for DTC Trading in the U.S.
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares listed in the United States, under the symbol APLIF, are Depository Trust Company (DTC) eligible. DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. DTC services provide simplification, convenience, and cost benefits for investors and brokers trading Canadian securities in the United States.
Aug 10, 2020 07:17 am ET
FDA Clears Appili Therapeutics to Expand its Phase 2 Clinical Trial of Favipiravir for the Potential Prevention of COVID-19 at U.S. Long-Term Care Facilities
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company clearance to proceed after Appili’s filing of an investigational new drug (IND) application for broad-spectrum antiviral favipiravir. Appili is expanding
Jul 30, 2020 07:17 am ET
Appili Prepares Canadian Long-Term Care Facilities to Enroll Participants in a Clinical Trial Evaluating Favipiravir as an Outbreak Control Agent Against COVID-19
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that the Company has initiated site screening of long term care (LTC) facilities in Ontario for its Phase 2 study evaluating favipiravir as a post-exposure outbreak control measure against COVID-19. Residents at screened sites will be eligible for enrollment and randomization into the trial upon confirmation of a COVID-19 outbreak. The trial is expected to ultimately enroll approximately 760 participants at 16 LTC facilities. A
Jun 24, 2020 05:22 pm ET
Appili Therapeutics Announces FY 2020 Annual and Financial Results
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today reported its financial and operational results for the year ended March 31, 2020.
Jun 15, 2020 07:17 am ET
Appili Therapeutics Commences Trading on the OTCQX Marketplace
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”) is pleased to announce today that its common shares began trading on the OTCQX Best Market®. The OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. Appili’s shares are trading under the ticker symbol “APLIF.”
Jun 15, 2020 07:00 am ET
OTC Markets Group Welcomes Appili Therapeutics Inc. to OTCQX
NEW YORK, June 15, 2020 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Appili Therapeutics Inc. (the "Company" or "Appili") (TSXV: APLI; OTCQX: APLIF), a biopharmaceutical company focused on anti-infective drug development, has qualified to trade on the OTCQX® Best Market.
Jun 10, 2020 09:18 am ET
Appili Therapeutics Announces Closing of Public Offering of $15,525,000 and Concurrent Private Placement of $1,440,000
Appili Therapeutics Inc. (TSXV:APLI) (the “Company” or “Appili”) announced the closing of its previously announced public offering (the “Public Offering”) of units (the “Units”). The Public Offering was made pursuant to an agency agreement entered into with a syndicate of agents led by Bloom Burton Securities Inc. (the “Lead Agent”) and including Mackie Research Capital Corporation, Industrial Alliance Securities Inc., Haywood Securities Inc., and Richardson GMP Limited (collectively with the Lead Agent, the “Agents”) and the Company.
Jun 05, 2020 08:05 pm ET
Appili Therapeutics Announces Filing of Prospectus Supplement and Proposed Concurrent Private Placement
Appili Therapeutics Inc. (TSXV:APLI) (the “Company” or “Appili”) announced today that it has filed a prospectus supplement to its base shelf prospectus dated September 19, 2019 (collectively, the “Prospectus Supplement”) in connection with its previously announced overnight marketed offering of equity securities (the "Public Offering"). The Prospectus Supplement was filed in each Province of Canada (other than Quebec) and a copy of the Prospectus Supplement will be available under the Company’s profile at
Jun 04, 2020 10:57 am ET
IIROC Trading Resumption - APLI
VANCOUVER, BC, June 4, 2020 /CNW/ - Trading resumes in:
Jun 04, 2020 10:33 am ET
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”) is pleased to announce today that it has priced its previously announced overnight marketed offering of equity securities (the "Offering"). Pursuant to the Offering, Appili will issue 11,250,000 units of the Company ("Units") at a price of C$1.20 per Unit (the “Offering Price”) for gross proceeds of C$13,500,000. Each Unit is comprised of one Class A common share of the Company (a "Common Share") and one-half (1/2) of one Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant is exercisable a
Jun 03, 2020 04:46 pm ET
Appili Therapeutics Announces Overnight Marketed Equity Offering
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, has announced today that it will undertake an overnight marketed public offering (the "Offering") of units (the "Units"), comprised of Class A common shares and Class A common share purchase warrants ("Warrants"). The Offering is to be effected on a best efforts agency basis in each Province of Canada (other than Quebec) by way of a prospectus supplement (the "Prospectus Supplement") to the Company's base shelf prospectus dated September 19, 2019 (together
Jun 03, 2020 03:43 pm ET
IIROC Trading Halt - APLI
VANCOUVER, BC, June 3, 2020 /CNW/ - The following issues have been halted by IIROC:
May 21, 2020 07:17 am ET
Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that Health Canada provided regulatory clearance for Appili’s Phase 2 study evaluating FUJIFILM Toyama Chemical’s (FFTC) favipiravir as a preventative measure against COVID-19 outbreaks.
May 11, 2020 10:05 am ET
IIROC Trading Resumption - APLI
VANCOUVER, May 11, 2020 /CNW/ - Trading resumes in:
May 11, 2020 08:30 am ET
IIROC Trading Halt - APLI
VANCOUVER, May 11, 2020 /CNW/ - The following issues have been halted by IIROC:
May 11, 2020 07:17 am ET
Appili Therapeutics Submits CTA with Health Canada to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama Chemical’s Favipiravir as a Preventative Measure Against COVID-19 in Canadi
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it will sponsor the first clinical trial evaluating FUJIFILM Toyama Chemical’s (FFTC) drug favipiravir for the prevention of COVID-19, a respiratory infection caused by the novel SARS-CoV-2 coronavirus. Favipiravir is approved in Japan as the anti-influenza drug Avigan. With FFTC providing support through donated drug product, the phase 2 study will be conducted at long-term care facilities in Ontario. Appili has filed the clinical tria
May 04, 2020 10:44 am ET
Appili Therapeutics to Present at Maxim Group’s Infectious Disease Virtual Conference
Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that Appili’s CEO Dr. Armand Balboni will be a panelist at the upcoming “Infectious Disease Virtual Conference” presented by Maxim Group. Dr. Balboni will be disc
Apr 21, 2020 07:17 am ET
Appili Therapeutics Names Infectious Disease Specialist Yoav Golan, MD, as its Chief Medical Officer
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has appointed Yoav Golan, MD, to serve as the Company’s first Chief Medical Officer (CMO). Dr. Golan has spent his more than 25 year-career as an infectious disease (ID) medical specialist, most recently serving as an attending physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, and as an associate professor at Tufts University School of Medicine in Boston. In his role as Appili’s CMO, Dr
Feb 27, 2020 05:05 pm ET
Appili Therapeutics Reports Financial and Operational Results for Third Quarter Fiscal Year 2020
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today reported its financial and operational results for the third quarter of its fiscal year 2020, ending December 31, 2019. ​
Feb 20, 2020 08:26 am ET
Appili Therapeutics Announces Closing of Public Offering of $10,250,000
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”) is pleased to announce the closing of its previously announced public offering (the “Offering”) of units (the “Units”). The Offering was made pursuant to an agency agreement entered into between Bloom Burton Securities Inc. (the “Lead Agent”), Mackie Research Capital Corporation, Haywood Securities Inc. and Industrial Alliance Securities Inc. (together with the Lead Agent, the “Agents”) and the Company.
Feb 14, 2020 07:30 am ET
Appili Therapeutics Announces Upsizing of Previously Announced Equity Offering
Appili Therapeutics Inc. (TSXV: APLI) (the "Company" or “Appili”) is pleased to announce today that it has increased the size of its previously announced offering of equity securities (the "Offering"). Pursuant to the revised terms of the Offering, Appili will issue an aggregate of 12,812,500 Units at a price of C$0.80 per Unit (the “Offering Price”) for aggregate gross proceeds of C$10,250,000. Each Unit is comprised of one Class A common share of the Company (a "Common Share") and one-half (1/2) of one Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant is exercisab
Feb 13, 2020 08:08 am ET
IIROC Trading Resumption - APLI
VANCOUVER, Feb. 13, 2020 /CNW/ - Trading resumes in:
Feb 13, 2020 07:30 am ET
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”) is pleased to announce today that it has priced its previously announced overnight marketed offering of equity securities (the "Offering"). Pursuant to the Offering, Appili will issue a minimum of 6,250,000 units of the Company ("Units") and a maximum of 8,750,000 Units at a price of C$0.80 per Unit (the “Offering Price”) for minimum gross proceeds of $5,000,000 (the “Minimum Offering”) and maximum gross proceeds of $7,000,000. Each Unit is comprised of one Class A common share of the Company (a "Common Share") and one-half (1/2
Feb 12, 2020 04:00 pm ET
Appili Therapeutics Announces Overnight Marketed Equity Offering
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, has announced today that it will undertake an overnight marketed public offering (the "Offering") of units (the "Units"), with each Unit composed of one Class A common share (each, a “Common Share”) and one-half (1/2) of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will be exercisable for one Common Share for a period of three years from the closing of the Offering. The Offering is to be effected on a best efforts agency
Feb 12, 2020 03:09 pm ET
IIROC Trading Halt - APLI
VANCOUVER, Feb. 12, 2020 /CNW/ - The following issues have been halted by IIROC:
Jan 28, 2020 07:17 am ET
Researchers Present Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2020 ASM Biothreats
Appili Therapeutics Inc. (TSXV: APLI) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that Dr. Carl Gelhaus, Senior Program Manager of the Medical Countermeasures Division at MRIGlobal, will present positive interim data on Appili’s ATI-1701 program at the 2020 ASM Bioth
Jan 27, 2020 07:17 am ET
Appili Therapeutics Appoints Veteran Biotech Executive Dr. Juergen Froehlich to Its Board of Directors
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has appointed Juergen Froehlich, MD, MBA, to its Board of Directors. Dr. Froehlich’s career covers a broad range of drug development successes involving strategic planning and execution of all phases of drug development and regulatory interactions across multiple therapeutic areas, including infectious diseases. In addition, Appili announced the appointment of current board member and Xenon Pharmaceuticals President and Chief Financi
Dec 03, 2019 07:17 am ET
Appili Therapeutics Enters Commercial Agreement With Saptalis Pharmaceuticals for Anticipated Launch of ATI-1501 Antibiotic Candidate in the U.S.
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has entered into a commercialization agreement with Saptalis Pharmaceuticals LLC, a New York-based specialty pharmaceuticals company, on ATI-1501, Appili’s liquid suspension reformulation of the antibiotic metronidazole. Under the terms of the agreement, Appili is eligible to receive multiple milestone and royalty payments on the sale of ATI-1501 in the U.S. In addition, Saptalis will be responsible for overseeing the regulatory revi
Dec 02, 2019 07:17 am ET
Appili Therapeutics Names Dr. Armand Balboni as Chief Executive Officer
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a clinical stage biopharmaceutical company developing anti-infective drug and vaccine candidates, announced that, effective today, it has appointed Dr. Armand Balboni to serve as its new Chief Executive Officer. As part of a planned transition, Dr. Balboni will replace former Chief Executive Officer Kevin Sullivan, who has resigned to pursue other opportunities. Dr. Balboni has served as Appili’s Chief Scientific Officer and a member of the Company’s board since 2018 and brings over 20 years of clinical and regulatory experienc
Nov 27, 2019 05:05 pm ET
Appili Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2020
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today reported its financial and operational results for the second quarter of its fiscal year 2020, ending September 30, 2019. ​
Nov 21, 2019 04:00 am ET
Appili Therapeutics Acquires Clinical Stage Antifungal Program From FUJIFILM Toyama Chemical
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a publicly traded biopharmaceutical company focused on anti-infective drug development, announced today it has signed an agreement with FUJIFILM Toyama Chemical Co., Ltd. to acquire and develop the novel antifungal drug T-2307, which will now be called ATI-2307. This drug candidate is a novel broad-spectrum antifungal agent that has been evaluated in multiple preclinical studies and three human Phase I clinical trials. Today’s agreement with FUJIFILM Toyama Chemical assigns Appili exclusive worldwide rights (ex-Japan) to develo
Nov 18, 2019 04:35 pm ET
Researchers Present New Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2019 Chemical and Biological Defense Science & Technology Conference
Appili Therapeutics Inc. (TSXV: APLI) (the Company or Appili), a biopharmaceutical company focused on anti-infective drug development, today announced that Dr. Carl Gelhaus, Senior Program Manager of the Medical Countermeasures Division at MRIGlobal, will present positive interim data on Appili’s ATI-1701 program at the
Sep 26, 2019 05:05 pm ET
Appili Therapeutics Announces Voting Results of Annual and Special Meeting of Shareholders
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced the voting results from its annual and special meeting of shareholders held on Thursday, September 26, 2019.
Sep 16, 2019 05:05 pm ET
Appili Therapeutics Retains BND Projects for Strategic Investor Relations Services
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has retained BND Projects Inc. (“BND”) to provide strategic investor relations services. BND will aid the Company in building awareness in the financial community by introducing, maintaining and protecting relationships between the management of the Company and professional investors.
Aug 21, 2019 05:05 pm ET
Appili Therapeutics Reports Financial Results for First Quarter of Fiscal Year 2020
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today reported its financial and operational results for the first quarter of its fiscal year 2020, which ended June 30, 2019. ​
Aug 20, 2019 07:17 am ET
Researchers to Present New Data on Appili Therapeutics Infectious Disease Programs at the 2019 Military Health System Research Symposium
Today, Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, will present updated data on the company’s ATI-1701 and ATI-1503 programs at the Military Health System Research Symposium (MHSRS). The conference is currently being held f
Jul 03, 2019 05:00 pm ET
Appili Therapeutics Announces FY 2019 Financial Results
Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced its financial and operational results for the year ended March 31, 2019. ​
Jul 03, 2019 10:33 am ET
Appili Therapeutics Inc. Opens the Market
TORONTO, July 3, 2019 /CNW/ - Kevin Sullivan, Chief Executive Officer, Appili Therapeutics Inc. (APLI), joined Tim Babcock, Managing Director, Capital Formation, TSX Venture Exchange, to open the market. Headquartered in Halifax, Nova Scotia, Appili is a biopharmaceutical company focused on the acquisition and development of novel treatments targeting unmet needs in infectious disease. Appili Therapeutics Inc. commenced trading on TSX Venture Exchange on June 25, 2019.
Jul 02, 2019 07:17 am ET
Appili Therapeutics Signs $3M USD Grant Contract with the United States Department of Defense to Develop Antibiotics that Target Superbugs
Appili Therapeutics Inc. (TSXV:APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that the United States Department of Defense, (DOD) Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program (PRMRP) has completed the contract awarding the Company a $3.0 million USD grant.